Elranatamab
Phase 3Monoclonal antibody
PfizerElranatamab is a monoclonal antibody that works as a T Cell Surface Glycoprotein CD3 Binding Agent; Tumor Necrosis Factor Receptor Superfamily Member 17 Binding Agent.[2] It is being investigated across 13 indications, with its most advanced program in Phase 3.[1]
Elranatamab is one of 125 small molecule programs targeting AL amyloidosis. It is currently in Phase 3.
13
Indications
49
Total Trials
39
Active Trials
124
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
259 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Fludara
SanofiPhase 3
TALVEY
Johnson & JohnsonPhase 3
Venclexta
AbbViePhase 3
Sarclisa
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Azatiq
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Cytosar
TevaPhase 3
BLENREP
GGlaxo Dba Glaxosmithkline
Phase 3
Sylvant
RRECORDATI GROUP
Phase 3
Elranatamab
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma26 trials
Show 23 more trials
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Recruiting·JJuno Therapeutics, Inc., a Bristol-Myers Squibb Company·Phase 1·NCT06121843·187 enrolled
Elranatamab5 trials
Show 2 more trials
Multiple Myeloma (MM)2 trials
Refractory Multiple Myeloma2 trials
13 more indications
Relapsed or Refractory1 trial
Multiple Myeloma, Refractory1 trial
Plasmablastic Lymphoma1 trial
Relapsed/Refractory Multiple Myeloma1 trial
Multiple Myeloma, Newly Diagnosed1 trial
Relapsed Refractory Multiple Myeloma (RRMM)1 trial
Smoldering Multiple Myeloma1 trial
Hemophilia A With Inhibitor1 trial
A Single-Arm, Open-Label, Exploratory Clinical Study to Evaluate the Safety and Efficacy of Elranatamab for Inhibitor Eradication in Patients With Moderate-to-Severe Hemophilia A With Inhibitors and Poor Prognosis for Inhibitor Eradication
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT07788469·20 enrolled
AL amyloidosis1 trial
Myeloma Multiple1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Elranatamab. EMBL-EBI & Wellcome Sanger Institute.
- [4]